Therapeutic Efficacy of Immunotherapy for Gastric Cancer Metastasis

Overview

Journal World J Gastrointest Surg

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2024 Dec 30

PMID 39734465

Authors

Fei-Fei Xie

Su-Ting Qian

Hao-Yu Zhao

Qing-Sheng Liu

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) metastasis is the main cause of poor prognosis for GC patients. In recent years, breakthroughs in immunotherapy have been made in the treatment of many kinds of cancers, providing new hope for patients with GC metastasis. This paper reviews the mechanism of immunotherapy in GC metastasis and its clinical application, and discusses and compares the research and efficacy of immunotherapy in patients with liver metastasis, lung metastasis, peritoneal metastasis and lymph node metastasis of GC. This study explores the challenges and future development directions of immunotherapy, and provides a theoretical basis and clinical guidance for the precise treatment of patients with GC metastasis.

References

Xu S, Lu Z . The role of LMNB2 as a diagnostic and prognostic biomarker in lung adenocarcinoma. Asian J Surg. 2024; . DOI: 10.1016/j.asjsur.2024.08.056. View

Xiaobin C, Zhaojun X, Tao L, Tianzeng D, Xuemei H, Fan Z . Analysis of Related Risk Factors and Prognostic Factors of Gastric Cancer with Bone Metastasis: A SEER-Based Study. J Immunol Res. 2022; 2022:3251051. PMC: 8863473. DOI: 10.1155/2022/3251051. View

Zhu Y, Chang X, Zhou R, Chen Y, Ma H, Xiao Z . Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer. Lung Cancer. 2022; 166:189-196. DOI: 10.1016/j.lungcan.2022.03.006. View

Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L . Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. JAMA. 2023; 330(21):2064-2074. PMC: 10698618. DOI: 10.1001/jama.2023.19918. View

Ajani J, DAmico T, Bentrem D, Chao J, Cooke D, Corvera C . Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(2):167-192. DOI: 10.6004/jnccn.2022.0008. View

Reck M, Remon J, Hellmann M . First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):586-597. DOI: 10.1200/JCO.21.01497. View

Chen C, Jung A, Yang A, Monroy I, Zhang Z, Chaurasiya S . Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies. Cancers (Basel). 2023; 15(23). PMC: 10705752. DOI: 10.3390/cancers15235661. View

Cheng R, Li B, Wang H, Zeng Y . Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway. Clin Transl Oncol. 2023; 25(11):3122-3138. DOI: 10.1007/s12094-023-03181-x. View

Guan W, He Y, Xu R . Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023; 16(1):57. PMC: 10225110. DOI: 10.1186/s13045-023-01451-3. View

10.

Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Ogino S . Tumor exosome-mediated promotion of adhesion to mesothelial cells in gastric cancer cells. Oncotarget. 2016; 7(35):56855-56863. PMC: 5302957. DOI: 10.18632/oncotarget.10869. View

11.

Shigenobu T, Ohtsuka T, Hanawa R, Sakamaki H, Yoshizu A, Tajima A . Prognostic Impact of Visceral Pleural Invasion in Resected Solitary Lung Metastases from Gastric Cancer. Ann Thorac Cardiovasc Surg. 2023; 29(6):279-286. PMC: 10767656. DOI: 10.5761/atcs.oa.23-00032. View

12.

Wang L, Liu S, Zhang S, Chen X, Huang T, Tian R . Gastric cancer liver metastasis will reduce the efficacy of immunotherapy. World J Gastrointest Surg. 2024; 16(9):2760-2764. PMC: 11438812. DOI: 10.4240/wjgs.v16.i9.2760. View

13.

Xu J, Liu H, Ni G, Huang Y, Huang Y, Liang H . Clinical efficacy of PD-1 inhibitor combined with radiotherapy in a multi-drug resistant patient with liver metastasis from gastric cancer. Front Surg. 2023; 10:1101294. PMC: 10157034. DOI: 10.3389/fsurg.2023.1101294. View

14.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

15.

Tu J, Xu H, Ma L, Li C, Qin W, Chen X . Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022; 12(2):747-766. PMC: 8692903. DOI: 10.7150/thno.65828. View

16.

Ye F, Dewanjee S, Li Y, Jha N, Chen Z, Kumar A . Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023; 22(1):105. PMC: 10324146. DOI: 10.1186/s12943-023-01805-y. View

17.

Yang W, Zhao H, Yu Y, Wang J, Guo L, Liu J . Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023; 29(16):2452-2468. PMC: 10167900. DOI: 10.3748/wjg.v29.i16.2452. View

18.

Zaremba A, Zimmer L, Griewank K, Ugurel S, Roesch A, Schadendorf D . [Immunotherapy for malignant melanoma]. Internist (Berl). 2020; 61(7):669-675. DOI: 10.1007/s00108-020-00812-1. View

19.

Crippa S, Angelini C, Mussi C, Bonardi C, Romano F, Sartori P . Surgical treatment of metastatic tumors to the pancreas: a single center experience and review of the literature. World J Surg. 2006; 30(8):1536-42. DOI: 10.1007/s00268-005-0464-4. View

20.

Kan N, Imamura M . [Loco-regional immunotherapy with OK-432 and cultured autologous lymphocytes for patients with metastatic cancer]. Hum Cell. 1993; 6(2):100-5. View